Given that the abnormal expression of FLT3 kinase, including amplified or aberrantly activated FLT3, is frequently observed in the blast cells of AML patients, FLT3 represents an attractive therapeutic target of choice for drugs development in AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.